Further exploration of molecular typing has led to further delineation of HER2- and clinical trials have demonstrated that patients with HER2 low-expressing breast cancers may derive more benefit from anti-HER2 ADCs and that HER2-ultralow expression also benefits from anti-HER2, which would provide new therapeutic options in clinical practice. Here, ERBB2 is linked to breast carcinoma.